Zacks Research Weighs in on Bone Biologics Q1 Earnings

Bone Biologics Corp. (NASDAQ:BBLG) – Investment analysts at Zacks Research issued their Q1 2026 earnings estimates for Bone Biologics in a report released on Tuesday, March 3rd. Zacks Research analyst B. Sorensen forecasts that the company will post earnings of ($0.54) per share for the quarter. The consensus estimate for Bone Biologics’ current full-year earnings is ($5.00) per share. Zacks Research also issued estimates for Bone Biologics’ Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.43) EPS and FY2027 earnings at ($1.62) EPS.

Separately, Weiss Ratings reiterated a “sell (e)” rating on shares of Bone Biologics in a report on Monday, December 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Bone Biologics Stock Performance

Shares of BBLG opened at $1.26 on Wednesday. Bone Biologics has a 1 year low of $1.11 and a 1 year high of $6.75. The company’s 50 day simple moving average is $1.48 and its 200 day simple moving average is $1.87. The company has a market capitalization of $2.26 million, a price-to-earnings ratio of -0.35 and a beta of 0.78.

Hedge Funds Weigh In On Bone Biologics

An institutional investor recently raised its position in Bone Biologics stock. DRW Securities LLC boosted its stake in shares of Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,576 shares of the company’s stock after purchasing an additional 12,549 shares during the period. DRW Securities LLC owned approximately 1.31% of Bone Biologics worth $34,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 34.30% of the company’s stock.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.